Literature DB >> 12675507

Medical management of pituitary adenomas: the special case of management of the pregnant woman.

Marcello Delano Bronstein1, Luiz Roberto Salgado, Nina Rosa de Castro Musolino.   

Abstract

The development of efficacious surgical and medical therapies for pituitary adenomas as well as the improvement of hormone therapy for ovulation induction has made pregnancy possible for women harboring pituitary tumors. However, gestational risks due to the possibility of tumor growth during pregnancy, mainly in women with macroadenomas, raise a concern. Bromocriptine has a well-established role for prolactinoma treatment before and during pregnancy, even when a symptomatic tumor increase occurs. It can also be used in acromegaly, despite its poorer results. Somatostatin analogs have been used in acromegaly even during pregnancy with uneventful outcomes, but their safety in pregnancy is not well established, yet. The largest experience with medical treatment for Cushing's disease during pregnancy involves metyrapone, a steroidogenesis inhibitor, without descriptions of congenital abnormalities. Concerning clinically non-functioning pituitary tumors, ovulation induction or even in vitro fertilization are frequently needed. The purpose of this review is to provide an update on therapeutic strategies to restore fertility as well as gestational and post-gestational management of patients with pituitary adenomas, focusing mainly on the role of medical treatment for different tumor types.

Entities:  

Mesh:

Year:  2002        PMID: 12675507     DOI: 10.1023/a:1022364514971

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  76 in total

1.  Pregnancy following 2-bromo-alpha-ergocryptine (CB-154)-induced ovulation in an acromegalic patient with galactorrhea and amenorrhea.

Authors:  T Aono; T Shioji; M Kohno; G Ueda; K Kurachi
Journal:  Fertil Steril       Date:  1976-03       Impact factor: 7.329

2.  Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.

Authors:  L Duranteau; P Chanson; A Lavoinne; S Horlait; J Lubetzki; J M Kuhn
Journal:  Clin Endocrinol (Oxf)       Date:  1991-01       Impact factor: 3.478

3.  Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.

Authors:  A Colao; A Di Sarno; F Sarnacchiaro; D Ferone; G Di Renzo; B Merola; L Annunziato; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-03       Impact factor: 5.958

4.  Acromegaly first diagnosed in pregnancy: the role of bromocriptine therapy.

Authors:  A S Yap; W M Clouston; R H Mortimer; R F Drake
Journal:  Am J Obstet Gynecol       Date:  1990-08       Impact factor: 8.661

5.  Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy.

Authors:  E Ciccarelli; S Grottoli; P Razzore; D Gaia; A Bertagna; S Cirillo; T Cammarota; M Camanni; F Camanni
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

Review 6.  Cushing's syndrome and pregnancy.

Authors:  L R Sheeler
Journal:  Endocrinol Metab Clin North Am       Date:  1994-09       Impact factor: 4.741

7.  Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline.

Authors:  T Lohmann; C Trantakis; M Biesold; S Prothmann; S Guenzel; R Schober; R Paschke
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

8.  Rapid regression through bromocriptine therapy of a suprasellar extending prolactinoma during pregnancy.

Authors:  S L Tan; H S Jacobs
Journal:  Int J Gynaecol Obstet       Date:  1986-06       Impact factor: 3.561

9.  Women with prolactinoma--effect of pregnancy and lactation on serum prolactin and on tumour growth.

Authors:  U Holmgren; G Bergstrand; K Hagenfeldt; S Werner
Journal:  Acta Endocrinol (Copenh)       Date:  1986-04

Review 10.  Mifepristone: treatment of Cushing's syndrome.

Authors:  O Sartor; G B Cutler
Journal:  Clin Obstet Gynecol       Date:  1996-06       Impact factor: 2.190

View more
  15 in total

1.  Clinical and biochemical improvement in acromegaly during pregnancy.

Authors:  S L Lau; S McGrath; D Evain-Brion; R Smith
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

Review 2.  Prolactinomas and pregnancy.

Authors:  Marcello Delano Bronstein
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 3.  Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature.

Authors:  Graciela Stalldecker; María Susana Mallea-Gil; Mirtha Guitelman; Analía Alfieri; María Carolina Ballarino; Laura Boero; Alberto Chervin; Karina Danilowicz; Sabrina Diez; Patricia Fainstein-Day; Natalia García-Basavilbaso; Mariela Glerean; Viviana Gollan; Débora Katz; Mónica Graciela Loto; Marcos Manavela; Amelia Susana Rogozinski; Marisa Servidio; Nicolás Marcelo Vitale
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

Review 4.  Managing Cushing's disease: the state of the art.

Authors:  Annamaria Colao; Marco Boscaro; Diego Ferone; Felipe F Casanueva
Journal:  Endocrine       Date:  2014-01-11       Impact factor: 3.633

5.  A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas.

Authors:  B G Sant' Anna; N R C Musolino; M R Gadelha; C Marques; M Castro; P C L Elias; L Vilar; R Lyra; M R A Martins; A R P Quidute; J Abucham; D Nazato; H M Garmes; M L C Fontana; C L Boguszewski; C B Bueno; M A Czepielewski; E S Portes; V S Nunes-Nogueira; A Ribeiro-Oliveira; R P V Francisco; M D Bronstein; A Glezer
Journal:  Pituitary       Date:  2020-04       Impact factor: 4.107

Review 6.  Management of pituitary tumors in pregnancy.

Authors:  Marcello D Bronstein; Diane B Paraiba; Raquel S Jallad
Journal:  Nat Rev Endocrinol       Date:  2011-03-15       Impact factor: 43.330

7.  Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients.

Authors:  Pouyan Famini; Marcel M Maya; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2011-04-06       Impact factor: 5.958

Review 8.  Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

Authors:  B M K Biller; A B Grossman; P M Stewart; S Melmed; X Bertagna; J Bertherat; M Buchfelder; A Colao; A R Hermus; L J Hofland; A Klibanski; A Lacroix; J R Lindsay; J Newell-Price; L K Nieman; S Petersenn; N Sonino; G K Stalla; B Swearingen; M L Vance; J A H Wass; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2008-04-15       Impact factor: 5.958

9.  Successful management of a pregnant woman with a TSH secreting pituitary adenoma with surgical and medical therapy.

Authors:  Sumapa Chaiamnuay; Mark Moster; M Richard Katz; Young Nam Kim
Journal:  Pituitary       Date:  2003-09       Impact factor: 4.107

10.  Management of prolactinomas in Brazil: an electronic survey.

Authors:  Lucio Vilar; Luciana Ansaneli Naves; Luiz Augusto Casulari; Monalisa Ferreira Azevedo; José Luciano Albuquerque; Fabiano Marcel Serfaty; Flavia R Pinho Barbosa; Antonio Ribeiro de Oliveira; Renan Magalhães Montenegro; Renan Magalhães Montenegro; Alberto José Santos Ramos; Manuel Dos Santos Faria; Nina Rosa C Musolino; Monica R Gadelha; Cesar Luiz Boguszewski; Marcello D Bronstein
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.